Chin Mark 4

What Happened

• Mark Chin, a director of Disc Medicine, received a grant/award of 6,212 derivative shares (transaction code A) on 2026-06-18. The reported acquisition price is $0.00, indicating an equity award/derivative grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-18; Filing date: 2026-06-23 (filed one business day after the typical 2-business-day Form 4 deadline).
• Shares/units granted: 6,212; reported acquisition price: $0.00.
• Shares owned after the transaction: Not specified in the excerpt provided.
• Footnote: The underlying shares vest upon the earlier of (i) the Company’s 2027 annual meeting or (ii) the one-year anniversary of the grant date, and only if Chin remains in service on the vesting date.
• Transaction type: Derivative award/grant (code A) — not a sale or open-market purchase.

Context

• This is an equity award that gives the reporting person a right to receive shares subject to vesting; it does not represent an immediate sale or cash proceeds. Such grants are commonly used for director compensation and do not, by themselves, indicate a buy/sell market signal.